title: Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.
abstract: The detection of autoantibodies in cancer patients has been shown to constitute an excellent tool for early diagnosis. Because breast cancer still lacks early diagnostic markers, we investigated novel tumor-associated antigens and related autoantibodies in sera from patients with early stage breast cancer compared to autoimmune disease, other cancers, and healthy volunteers, using a proteomics-based approach. Among the 26 protein antigens specifically recognized by early stage breast cancer sera, we focused on Heat Shock Protein 60 (HSP60). Using ELISA, we investigated the frequency of autoantibodies directed against this protein in the sera of 240 individuals, comprising patients with either ductal carcinoma in situ (DCIS) ( n = 49) or early stage breast cancer ( n = 58), other cancers ( n = 20), autoimmune disease ( n = 20), and healthy subjects ( n = 93). Autoantibodies directed against HSP60 were present in 16/49 (31%) early stage breast cancer and 18/58 (32.6%) DCIS patients, compared to 4/93 (4.3%) healthy subjects. In particular, autoantibodies were present in 11/23 patients (47.8%) with high-grade DCIS, compared to 5/26 (19.2%) with low-grade DCIS. HSP60 mRNA levels were significantly higher in primary breast cancer compared to healthy breast tissues. Using immunohistochemistry, we found that HSP60 expression gradually increases from normal through DCIS to invasive tissues. Our results indicate that HSP60 autoantibodies may be of interest in terms of clinical utility for the early diagnosis of breast cancer and more particularly in DCIS. Moreover, HSP60 overexpression during the first steps of breast carcinogenesis may be functionally correlated to tumor growth and/or progression.
authors.affiliation: Department of Cellular Biology, CHU Montpellier, Hopital Arnaud de Villeneuve, Montpellier, France.
authors.forename: C
authors.initials: C
authors.lastname: Desmetz
authors.forename: F
authors.initials: F
authors.lastname: Bibeau
authors.forename: F
authors.initials: F
authors.lastname: Boissière
authors.forename: V
authors.initials: V
authors.lastname: Bellet
authors.forename: P
authors.initials: P
authors.lastname: Rouanet
authors.forename: T
authors.initials: T
authors.lastname: Maudelonde
authors.forename: A
authors.initials: A
authors.lastname: Mangé
authors.forename: J
authors.initials: J
authors.lastname: Solassol
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000595:Amino Acid Sequence; D000951:Antigens, Neoplasm / Q000378:metabolism*; D001483:Base Sequence; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism*; D002278:Carcinoma in Situ / Q000378:metabolism*; D044584:Carcinoma, Ductal / Q000378:metabolism*; D045744:Cell Line, Tumor; D018834:Chaperonin 60 / Q000737:chemistry / Q000276:immunology*; D017931:DNA Primers; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008875:Middle Aged; D008969:Molecular Sequence Data; D040901:Proteomics
chemical_list: D000951:Antigens, Neoplasm; D018834:Chaperonin 60; D017931:DNA Primers